Basic Information
RNALocate ID: | RLID:01001385 |
RNA Symbol: | hsa-miR-30a-3p |
Localization: | Mitochondrion |
RNA Information
RNA Name: | hsa-miR-30a* |
RNA ID: | miRBase:MIMAT0000088 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 22984580 |
Tissue/Cell Line: | Cell line (HEK-293|HeLa) |
Method: | Next-generation RNA sequencing |
Description: | The differential association of miRNA to mitochondria of both HEK293 and HeLa has been summarized in Table S3. Data are collected from Table S3: Pattern of miRNAs associated with mitochondria of HEK293 and HeLa. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001384 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:11000914 | Exosome | Brain tissue | 23382797 |
RLID:11000915 | Exosome | Plasma | 23663360 |
RLID:11000916 | Microvesicle | Seminal plasma | 23539611 |
RLID:11000917 | Microvesicle | Follicular fluid | 23666971 |
RLID:11000918 | Microvesicle | Serum | 24797360 |
RLID-D:11000024 | Exosome | Breast milk|Endothelial cells|Epithelial cells|Tongue tissue | |
RLID-D:11000287 | Microvesicle | Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-30a-3p | Splenic marginal zone lymphoma | MNDR-E-MI-36588 |
MNDR | hsa-miR-30a-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-36589 |
MNDR | hsa-miR-30a-3p | Oral squamous cell carcinoma | MNDR-E-MI-36590 |
MNDR | hsa-miR-30a-3p | Large cell neuroendocrine cancer | MNDR-E-MI-36591 |
MNDR | hsa-miR-30a-3p | Ovarian clear cell carcinoma | MNDR-E-MI-36592 |
MNDR | hsa-miR-30a-3p | Lymphoma | MNDR-E-MI-36593 |
MNDR | hsa-miR-30a-3p | Lymphoma non-hodgkin | MNDR-E-MI-36594 |
MNDR | hsa-miR-30a-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-36595 |
MNDR | hsa-miR-30a-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-36596 |
MNDR | hsa-miR-30a-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-36597 |
MNDR | hsa-miR-30a-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-36598 |
MNDR | hsa-miR-30a-3p | Her2-receptor positive breast cancer | MNDR-E-MI-36599 |
MNDR | hsa-miR-30a-3p | Niemann-pick disease type c | MNDR-E-MI-36600 |
MNDR | hsa-miR-30a-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-36601 |
MNDR | hsa-miR-30a-3p | Autosomal recessive limb-girdle muscular dystrophy type 2a | MNDR-E-MI-36602 |
MNDR | hsa-miR-30a-3p | Dermatomyositis | MNDR-E-MI-36603 |
MNDR | hsa-miR-30a-3p | Prostate cancer | MNDR-E-MI-36604 |
MNDR | hsa-miR-30a-3p | Gastric cancer | MNDR-E-MI-36605 |
MNDR | hsa-miR-30a-3p | Gastric lymphoma | MNDR-E-MI-36606 |
MNDR | hsa-miR-30a-3p | Alzheimer disease | MNDR-E-MI-36607 |
MNDR | hsa-miR-30a-3p | Bladder cancer | MNDR-E-MI-36608 |
MNDR | hsa-miR-30a-3p | Esophageal carcinoma | MNDR-E-MI-36609 |
MNDR | hsa-miR-30a-3p | Distal muscular dystrophy | MNDR-E-MI-36610 |
MNDR | hsa-miR-30a-3p | Duchenne muscular dystrophy | MNDR-E-MI-36611 |
MNDR | hsa-miR-30a-3p | Seizures | MNDR-E-MI-36612 |
MNDR | hsa-miR-30a-3p | Head and neck cancer | MNDR-E-MI-36613 |
MNDR | hsa-miR-30a-3p | Huntington disease | MNDR-E-MI-36614 |
MNDR | hsa-miR-30a-3p | Cardiovascular disease | MNDR-E-MI-36615 |
MNDR | hsa-miR-30a-3p | Lung cancer | MNDR-E-MI-36616 |
MNDR | hsa-miR-30a-3p | Parkinson disease | MNDR-E-MI-36617 |
MNDR | hsa-miR-30a-3p | Niemann-pick disease | MNDR-E-MI-36618 |
MNDR | hsa-miR-30a-3p | Basal-like breast cancer | MNDR-E-MI-36619 |
MNDR | hsa-miR-30a-3p | Thyroid cancer | MNDR-E-MI-36620 |
MNDR | hsa-miR-30a-3p | Pancreatic cancer | MNDR-E-MI-36621 |
MNDR | hsa-miR-30a-3p | Melanoma | MNDR-E-MI-36622 |
MNDR | hsa-miR-30a-3p | Rectum adenocarcinoma | MNDR-E-MI-36623 |
MNDR | hsa-miR-30a-3p | Nephroblastoma | MNDR-E-MI-36624 |
MNDR | hsa-miR-30a-3p | Colon cancer | MNDR-E-MI-36625 |
MNDR | hsa-miR-30a-3p | Ischemic attack transient | MNDR-E-MI-36626 |
MNDR | hsa-miR-30a-3p | Colon adenocarcinoma | MNDR-E-MI-36627 |
MNDR | hsa-miR-30a-3p | Relapsing-remitting multiple sclerosis | MNDR-E-MI-36628 |
MNDR | hsa-miR-30a-3p | Familial ovarian cancer | MNDR-E-MI-36629 |
MNDR | hsa-miR-30a-3p | Prostate adenocarcinoma | MNDR-E-MI-36630 |
MNDR | hsa-miR-30a-3p | Kidney cancer | MNDR-E-MI-36631 |
MNDR | hsa-miR-30a-3p | Carcinoma ductal breast | MNDR-E-MI-36632 |
MNDR | hsa-miR-30a-3p | Glioblastoma | MNDR-E-MI-36633 |
MNDR | hsa-miR-30a-3p | Malignant glioma | MNDR-E-MI-36634 |
MNDR | hsa-miR-30a-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-36635 |
MNDR | hsa-miR-30a-3p | Nemaline myopathy | MNDR-E-MI-36636 |
MNDR | hsa-miR-30a-3p | Inclusion body myositis | MNDR-E-MI-36637 |
MNDR | hsa-miR-30a-3p | Infarction middle cerebral artery | MNDR-E-MI-36638 |
MNDR | hsa-miR-30a-3p | Meningioma | MNDR-E-MI-36639 |
MNDR | hsa-miR-30a-3p | Gastric adenocarcinoma | MNDR-E-MI-36640 |
MNDR | hsa-miR-30a-3p | Lung squamous cell carcinoma | MNDR-E-MI-36641 |
MNDR | hsa-miR-30a-3p | Lung adenocarcinoma | MNDR-E-MI-36642 |
MNDR | hsa-miR-30a-3p | Adrenocortical cancer | MNDR-E-MI-36643 |
MNDR | hsa-miR-30a-3p | Thyroid carcinoma | MNDR-E-MI-36644 |
MNDR | hsa-miR-30a-3p | Bladder urothelial carcinoma | MNDR-E-MI-36645 |
MNDR | hsa-miR-30a-3p | Pancreatic adenocarcinoma | MNDR-E-MI-36646 |
MNDR | hsa-miR-30a-3p | Carcinoma renal cell | MNDR-E-MI-36647 |
MNDR | hsa-miR-30a-3p | Clear cell renal cell carcinoma | MNDR-E-MI-36648 |
MNDR | hsa-miR-30a-3p | Large cell carcinoma | MNDR-E-MI-36649 |
MNDR | hsa-miR-30a-3p | Esophageal cancer | MNDR-E-MI-36650 |
MNDR | hsa-miR-30a-3p | Lung small cell carcinoma | MNDR-E-MI-36651 |
MNDR | hsa-miR-30a-3p | Synovial sarcoma | MNDR-E-MI-36652 |
MNDR | hsa-miR-30a-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-36653 |
MNDR | hsa-miR-30a-3p | Breast invasive carcinoma | MNDR-E-MI-36654 |
MNDR | hsa-miR-30a-3p | Hepatocellular carcinoma | MNDR-E-MI-36655 |
MNDR | hsa-miR-30a-3p | Embryonal cancer | MNDR-E-MI-36656 |
MNDR | hsa-miR-30a-3p | Familiar ovarian carcinoma | MNDR-E-MI-36657 |
MNDR | hsa-miR-30a-3p | B-cell lymphoma | MNDR-E-MI-36658 |
MNDR | hsa-miR-30a-3p | Rheumatoid arthritis | MNDR-E-MI-36659 |
MNDR | hsa-miR-30a-3p | Hodgkin lymphoma | MNDR-E-MI-36660 |
MNDR | hsa-miR-30a-3p | Burkitt lymphoma | MNDR-E-MI-36661 |
MNDR | hsa-miR-30a-3p | Skin cutaneous melanoma | MNDR-E-MI-36662 |
MNDR | hsa-miR-30a-3p | Skin melanoma | MNDR-E-MI-36663 |
MNDR | hsa-miR-30a-3p | Acute myeloid leukemia | MNDR-E-MI-36664 |
MNDR | hsa-miR-30a-3p | Colorectal cancer | MNDR-E-MI-36665 |
MNDR | hsa-miR-30a-3p | Nasopharynx carcinoma | MNDR-E-MI-36666 |
MNDR | hsa-miR-30a-3p | Acute lymphocytic leukemia | MNDR-E-MI-36667 |
MNDR | hsa-miR-30a-3p | Cardiomegaly | MNDR-E-MI-36668 |
MNDR | hsa-miR-30a-3p | Nasopharyngeal cancer | MNDR-E-MI-36669 |
MNDR | hsa-miR-30a-3p | Prostatic neoplasms | MNDR-E-MI-36670 |
MNDR | hsa-miR-30a-3p | Polymyositis | MNDR-E-MI-36671 |
MNDR | hsa-miR-30a-3p | Peripheral nerve injuries | MNDR-E-MI-36672 |
MNDR | hsa-miR-30a-3p | Chronic pain | MNDR-E-MI-36673 |
MNDR | hsa-miR-30a-3p | Breast cancer her3+ negative | MNDR-E-MI-36674 |
MNDR | hsa-miR-30a-3p | Duke B | MNDR-E-MI-36675 |
MNDR | hsa-miR-30a-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-36676 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ATF3 | Homo sapiens | RR00155507 |
TOP